Innovation at Penn
Browse Penn-owned technologies available for licensing.
Search Results - roger greenberg
Novel class of therapeutics for treatment of lupus and other autoimmune and inflammatory conditions
First in class compounds inhibiting BRISC deubiquitinating enzymes for treatment of autoimmune diseases. Problem: Lupus is an autoimmune disease affecting approximately 5 million people worldwide. Lupus results in a hyperactive immune system and multisystem pathologic changes to joints, skin, kidneys, blood cells, and lungs. Immunosuppressive...
Therapeutics & Vaccines
© 2020. All Rights Reserved. Powered by